Eris Lifesciences announced its unaudited standalone and consolidated financial results for Q2 (Jul-Sep) and H1 (Apr-Sep) ended September 30, 2025. The board also approved the re-appointment of Mr. Krishnakumar Vaidyanathan as Whole Time Director and Ms. Kalpana Unadkat as an Independent Director.
Financial Performance Highlights
Eris Lifesciences reported the following key consolidated financial results for the quarter ended September 30, 2025:
- Revenue from operations: ₹792.41 Crore
- Net profit for the period: ₹134.47 Crore
- Total comprehensive income: ₹133.90 Crore
For the half year ended September 30, 2025:
- Revenue from operations: ₹1,565.41 Crore
- Net profit for the period: ₹259.57 Crore
- Total comprehensive income: ₹258.43 Crore
Standalone Financial Performance
Key standalone financial results for the quarter ended September 30, 2025 include:
- Revenue from operations: ₹650.50 Crore
- Net profit for the period: ₹149.57 Crore
For the half year ended September 30, 2025:
- Revenue from operations: ₹1,229.14 Crore
- Net profit for the period: ₹249.56 Crore
Director Re-appointments
The Board has approved the re-appointment of Mr. Krishnakumar Vaidyanathan as Whole Time Director for a term of 5 years, effective from September 01, 2026, until August 31, 2031.
Furthermore, Ms. Kalpana Unadkat has been re-appointed as an Independent Director for a period of 5 years, commencing from January 05, 2026, till January 04, 2031.
Source: BSE
